LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Cellink Relaunches Real-Time qPCR Instrument for COVID-19

By LabMedica International staff writers
Posted on 04 Apr 2020
Illustration
Illustration
CELLINK (Boston, MA, USA) has begun reselling its qPCR instrument which can be used for the quantification and genotyping of human viral pathogens, such as SARS-CoV-2. CELLINK is offering the instrument at a low-cost point to help advance research related to the COVID-19 pandemic and provide scientists with the tools they need to make a difference.

CELLINK is a niche life-science company that develops and delivers life-science solutions for cell culturing. It focuses on three application areas, including bioprinting, analysis and liquid handling & bioprocessing to deliver a complete solution in its life science niche. The company targets to develop and commercialize cell culture technologies, enabling researchers to print human organs and tissues for pharmaceutical and cosmetic applications.

CELLINK’s qPCR instrument for the quantification and genotyping of human viral pathogens, such as SARS-CoV-2, uses a laboratory technique of molecular biology based on the polymerase chain reaction. It monitors the amplification of a targeted DNA molecule during the PCR (i.e., in real time). The instrument includes dual channels and is open source, allowing users to use any kit to run their samples. It is designed as a high-quality, low-throughput qPCR cycler. The instrument is easy to use and runs a sample in 20-40 minutes.

Related Links:
CELLINK

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Sample Transportation System
Tempus1800 Necto

Channels

Hematology

view channel
Image: Research has linked platelet aggregation in midlife blood samples to early brain markers of Alzheimer’s (Photo courtesy of Shutterstock)

Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk

Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
GLOBE SCIENTIFIC, LLC